People living with obesity and related conditions often face challenges beyond weight management, including comorbidities, stigma, and bias.

Obesity is a complex biological disease that increases the risk of many other serious diseases and conditions, including Type 2 diabetes, heart failure, kidney disease, sleep apnea, atherosclerotic cardiovascular disease and metabolic dysfunction-associated steatohepatitis.^1,2 In 2022, 890 million adults (18 years and older) globally were living with obesity, and 2.5 billion adults were living with overweight.³

Obesity is linked to a marked reduction in quality of life and an array of serious medical complications and conditions.³ Despite the breadth of the disease, the formal recognition of obesity as a chronic disease by the American Medical Association (2013) and the European Health Commission (2021), and medical guidelines recommending pharmacologic treatment in appropriate individuals, only 1%-3% of eligible adults in the U.S. are prescribed medication for chronic weight management.^4-6 Addressing the needs of this community is a challenge that we take seriously and view as critical for public health.

In addition to our lead asset maridebart cafraglutide, also known as MariTide (formerly AMG 133), Amgen is also advancing an obesity pipeline, which includes both oral and injectable approaches, composed of both incretin and non-incretin mechanisms. Given the heterogeneity of obesity and the number of people impacted, a variety of approaches will be needed to meet the dynamic needs of people living with overweight, obesity and related conditions, underscoring our commitment to innovation and patient care.